259 results on '"Shaw, Timothy I."'
Search Results
2. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication
3. Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages
4. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children’s Oncology Group AREN18B5-Q
5. PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
6. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
7. CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax
8. Alzheimer’s disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment
9. Adapterama II: universal amplicon sequencing on Illumina platforms (TaggiMatrix).
10. 898 Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma
11. The landscape of coding RNA editing events in pediatric cancer
12. Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL)
13. Assemblathon 2: evaluating de novo methods of genome assembly in three vertebrate species
14. An Epigenomic fingerprint of human cancers by landscape interrogation of super enhancers at the constituent level.
15. Assemblathon 2: evaluating de novo methods of genome assembly in three vertebrate species
16. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo
17. Bcl11b sustains multipotency and restricts effector programs of intestinal-resident memory CD8 + T cells
18. Data from Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
19. Abstract 5704: An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma
20. Supplementary Figures 11-18 from Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin
21. Supplementary Figures 1-7 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma
22. Supplementary Tables 1-5 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma
23. Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures
24. The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study
25. Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
26. Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes
27. Malignant Progression of an Ancestral Bone Marrow Clone Harboring a CIC-NUTM2A Fusion in Isolated Myeloid Sarcoma
28. CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax
29. Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients
30. Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
31. A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML
32. Additional file 9 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
33. Additional file 1 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
34. Additional file 2 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
35. Additional file 4 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
36. Additional file 6 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
37. Additional file 5 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
38. Additional file 7 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
39. Additional file 3 of PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing
40. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses
41. Integrative Proteomics and Phosphoproteomics Profiling Reveals Dynamic Signaling Networks and Bioenergetics Pathways Underlying T Cell Activation
42. Bcl11b sustains multipotency and restricts effector programs of intestinal-resident memory CD8+ T cells.
43. Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo
44. Summarizing internal dynamics boosts differential analysis and functional interpretation of super enhancers
45. Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures
46. DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets
47. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes
48. Chromatin architecture at susceptible gene loci in cerebellar Purkinje cells characterizes DNA damage–induced neurodegeneration
49. EZH2-Mediated MHC Class II Silencing Drives Immune Evasion in AML with t(16;21) (FUS-ERG)
50. ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.